Home > Insider Trading > Filing (0001567619-21-017624)

Filing Details

Accession Number:: 0001567619-21-017624
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-09-29 16:05:11
Reporting Period:: 2021-09-27

Accepted Time:: 2021-09-29 16:05:11
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1650648	4D Molecular Therapeutics Inc.	FDMT	Biological Products, (No Disgnostic Substances) (2836)	473506994

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1692929	David Schaffer	C/O 4D Molecular Therapeutics Inc. 5858 Horton Street #455 Emeryville CA 94608		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2021-09-27	13,075	$32.59	986,925	No	4	S	Direct
Common Stock	Disposition	2021-09-27	6,157	$33.51	980,768	No	4	S	Direct
Common Stock	Disposition	2021-09-27	100	$34.19	980,668	No	4	S	Direct
Common Stock	Disposition	2021-09-28	13,812	$30.52	966,856	No	4	S	Direct
Common Stock	Disposition	2021-09-28	100	$32.00	966,756	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.
The transaction was executed in multiple trades in prices ranging from $32.09 to $33.09, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Since the date of the reporting person's last ownership report, he transferred 1,000,000 shares of FDMT common stock to his ex-spouse pursuant to a domestic relations order. The reporting person no longer reports as beneficially owned any securities owned by his ex-spouse.
The transaction was executed in multiple trades in prices ranging from $33.10 to $34.01, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The transaction was executed in multiple trades in prices ranging from $30.28 to $31.19, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.